Among the 43 CK+ informative cases, an overall concordance of 93% between CTCs and the primary tumor was observed with regards to HER2 status. Concordance was observed in 18 of 19 cases with positive HER2 status (positive predictive value of 90%) and 22 of 24 cases with negative HER2 status (negative predictive value of 96%). There was no difference between the numbers of CK+ CTCs detected in the 19 patients with HER2+ status compared to the 24 HER2-cases (median 5 and 9 CTCs, respectively, p = 0.37). Discordance was observed in three cases as shown in Table 2 .
The CEE TM platform utilizes an antibody cocktail to enable capture of a more heterogeneous CTC population based on the identification of HER2 gene amplification by FISH in both CK+/CD45-and CK-/CD45-cells.
These results strongly indicate that CK-/CD45-cells are in fact CTCs that have presumably downregulated CK expression below visible detection levels. Thus, studies that are limited to the use of EpCAM and CK for capture/enrichment and detection of CTCs, respectively, may not observe significant concordance of tumor biomarkers such as HER2 between CTCs and primary tumor.
Though some discordance between tumor and CTCs is perhaps expected given tumor heterogeneity, biopsy size, and robustness of the technical assay (especially for IHC), a bloodbased CTC assay may offer more reliable testing given the advantages of simple repeat testing the use of larger blood volumes when needed to ensure informative results. method were used to recover the peripheral blood mononuclear cell fraction (PBMC). Fc blocker (100ug/mL) and a capture antibody cocktail (1µg/mL of each antibody in the cocktail) were added for 30 minutes at room temperature to the recovered PBMC fraction. Following a wash and centrifugation, biotinylated secondary antibody was added for 30 minutes at room temperature. Following washing the final pellets were subsequently applied to the CEE TM microchannels. CTC Enrichment and Detection CEE TM microchannels are manufactured at Biocept, Inc. (San Diego, CA). The cell fraction is run through the microchannel and the captured cells stained with a mixture of anti-cytokeratin antibodies labeled with AlexaFluor-488. Cells were simultaneously stained with anti-CD45 labeled with AlexaFluor-594. The microchannels undergo microscopic analysis for enumeration of CK+/CD45-/DAPI+ (criteria for CTC identification), CK-/CD45+/DAPI+ (criteria for background WBCs) and CK-/CD45-/DAPI+ (possible CTCs that lack CK) cells. Fluorescent in situ hybridization Following CTC enumeration, the CEE TM microchannels were processed for multi-color FISH using the FDA-approved PathVysion HER2 DNA Probe Kit (centromere 17 specific probe, CEP 17-Spectrum Green; and locus specific HER2 probe, Spectrum Orange) and a centromere specific probe to chromosome 8 (CEP 8, Spectrum Aqua, Abbott Molecular, Abbott Park, IL) for use as an internal control for ploidy status. The ratio of HER2:CEP 17 was calculated and a ratio >2.2 in any CK+ /CD45-or CK-/CD45-cell was regarded as positive for HER2 gene amplification.
Patient characteristics are shown in Table 1 . Following enumeration, 43 patients were found to have ≥1 CTC identified based on a staining pattern of CK+/CD45-cells (prevalence of 80% based on CK+ staining). Abbreviations: CK = cytokeratin; CTC = circulating tumor cell; ER = estrogen receptor; n = node; PgR = progesterone receptor The CEE TM technology provides a sensitive platform for enhanced capture, detection and characterization of both CK+ and CK-CTCs.
This platform allows for evaluation of HER2 gene amplification status by FISH in intact CTCs within the microchannels at sensitivity and accuracy levels suitable for standardized CLIA-laboratory testing. 
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